Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel H Fowler

Showing results (21-30 of 100) with videos related to

Pageof 10
Sort By:
Blood|September 20, 2002
Interleukin 7 worsens graft-versus-host diseaseManoj L Sinha, Terry J Fry, Daniel H Fowler, et al.
Blood|July 12, 2003
CD3/CD28-costimulated T1 and T2 subsets: differential in vivo allosensitization generates distinct GVT and GVHD effectsUnsu Jung, Jason E Foley, Andreas A Erdmann, et al.
Blood|July 16, 2008
Graft rejection as a Th1-type process amenable to regulation by donor Th2-type cells through an interleukin-4/STAT6 pathwayJacopo Mariotti, Jason Foley, Kaitlyn Ryan, et al.
Blood|March 9, 2007
Direct inhibition of CD40L expression can contribute to the clinical efficacy of daclizumab independently of its effects on cell division and Th1/Th2 cytokine productionJames T Snyder, Jijia Shen, Hooman Azmi, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 26, 2012
Cell fate control gene therapy based on engineered variants of human deoxycytidine kinaseAnton Neschadim, James C M Wang, Takeya Sato, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 22, 2006
Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapyUnsu Jung, Jason E Foley, Andreas A Erdmann, et al.
Journal of Translational Medicine|September 17, 2014
Counter-flow elutriation of clinical peripheral blood mononuclear cell concentrates for the production of dendritic and T cell therapiesDavid F Stroncek, Vicki Fellowes, Chauha Pham, et al.
Autophagy|May 2, 2013
Harnessing autophagy for cell fate control gene therapyTania C Felizardo, Jason Foley, Kevin Steed, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 27, 2009
Assessment of the hematopoietic cell transplantation comorbidity index in non-Hodgkin lymphoma patients receiving reduced-intensity allogeneic hematopoietic stem cell transplantationSeth M Pollack, Seth M Steinberg, Jeanne Odom, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 18, 2007
Multiple reduced-intensity conditioning regimens facilitate correction of Fabry mice after transplantation of transduced cellsSheng-Ben Liang, Makoto Yoshimitsu, Armando Poeppl, et al.
Pageof 10

Showing results (21-30 of 100) with videos related to

Sort By:
Pageof 10
Blood|September 20, 2002
Interleukin 7 worsens graft-versus-host diseaseManoj L Sinha, Terry J Fry, Daniel H Fowler, et al.
Blood|July 12, 2003
CD3/CD28-costimulated T1 and T2 subsets: differential in vivo allosensitization generates distinct GVT and GVHD effectsUnsu Jung, Jason E Foley, Andreas A Erdmann, et al.
Blood|July 16, 2008
Graft rejection as a Th1-type process amenable to regulation by donor Th2-type cells through an interleukin-4/STAT6 pathwayJacopo Mariotti, Jason Foley, Kaitlyn Ryan, et al.
Blood|March 9, 2007
Direct inhibition of CD40L expression can contribute to the clinical efficacy of daclizumab independently of its effects on cell division and Th1/Th2 cytokine productionJames T Snyder, Jijia Shen, Hooman Azmi, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 26, 2012
Cell fate control gene therapy based on engineered variants of human deoxycytidine kinaseAnton Neschadim, James C M Wang, Takeya Sato, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 22, 2006
Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapyUnsu Jung, Jason E Foley, Andreas A Erdmann, et al.
Journal of Translational Medicine|September 17, 2014
Counter-flow elutriation of clinical peripheral blood mononuclear cell concentrates for the production of dendritic and T cell therapiesDavid F Stroncek, Vicki Fellowes, Chauha Pham, et al.
Autophagy|May 2, 2013
Harnessing autophagy for cell fate control gene therapyTania C Felizardo, Jason Foley, Kevin Steed, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 27, 2009
Assessment of the hematopoietic cell transplantation comorbidity index in non-Hodgkin lymphoma patients receiving reduced-intensity allogeneic hematopoietic stem cell transplantationSeth M Pollack, Seth M Steinberg, Jeanne Odom, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 18, 2007
Multiple reduced-intensity conditioning regimens facilitate correction of Fabry mice after transplantation of transduced cellsSheng-Ben Liang, Makoto Yoshimitsu, Armando Poeppl, et al.
Pageof 10